We present the case of a 51-year-old woman with a follicular variant of papillary thyroid carcinoma. After surgery she experienced a relapse. Chemotherapy treatment led only to disease stabilization. In August 2009, we decided to start therapy with sunitinib 50 mg daily in an intermittent schedule (4 weeks on/2 weeks off). A CT scan after 3 months of treatment showed partial remission of disease according to the RE-CIST criteria. The patient continued sunitinib until January 2011, when CT evidenced progression in the mediastinal lymph nodes and pleura. Genetic analyses were carried out to determine if the clinical response in our patient was correlated with the presence of RET or BRAF mutations. No RET/PTC rearrangements or BRAF-V600E mutation, which are the two most common genetic alterations detected in papillary thyroid carcinoma, were found. It can be hypothesized that the activity of sunitinib in this patient was due to its antiangiogenic properties.
AntonelliA., BocciG., La MottaC., FerrariS.M., FallahiP., FioravantiA., SartiniS., MinutoM., PiaggiS., CortiA., AlìG., BertiP., FontaniniG., DanesiR., Da SettimoF., MiccoliP.: Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer. J Clin Endocrinol Metab, 96: E288–296, 2011.
13.
BibleK.C., SumanV.J., MolinaJ.R., SmallridgeR.C., MaplesW.J., MenefeeM.E., RubinJ., SiderasK., MorrisJC3rd, McIverB., BurtonJ.K., WebsterK.P., BieberC., TraynorA.M., FlynnP.J., GohB.C., TangH., IvyS.P., ErlichmanC.; Endocrine Malignancies Disease Oriented Group; Mayo Clinic Cancer Center; Mayo Phase 2 Consortium: Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol, 11: 962–972, 2010.
14.
Gupta-AbramsonV., TroxelA.B., NelloreA., PuttaswamyK., RedlingerM., RansoneK., MandelS.J., FlahertyK.T., LoevnerL.A., O'DwyerP.J., BroseM.S.: Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol, 26: 4714–4719, 2008.
BroseM.S.: Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: the phase III DECISION trial. J Clin Oncol, 31(15S): abstract 4, 2013.
17.
CohenE.E., RosenL.S., VokesE.E., KiesM.S., ForastiereA.A., WordenF.P., KaneM.A., ShermanE., KimS., BycottP., TortoriciM., ShalinskyD.R., LiauK.F., CohenR.B.: Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol, 26: 4708–4713, 2008.
18.
AinK.B.: Phase II study of lenalidomide in distantly metastatic, rapidly progressive, and radioiodine-unresponsive thyroid carcinomas: preliminary Results. J Clin Oncol, 26(15S): abstract 6027, 2008.
19.
AinK.B., WilliamsK.D.: Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas. Thyroid, 17: 663–670, 2007.
20.
AntonelliA., BocciG., La MottaC., FerrariS.M., FallahiP., RuffilliI., Di DomenicantonioA., FioravantiA., SartiniS., MinutoM., PiaggiS., CortiA., AlìG., Di DesideroT., BertiP., FontaniniG., DanesiR., Da SettimoF., MiccoliP.: CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo. J Clin Endocrinol Metab, 97: E528–536, 2012.
